The charts on this page feature a breakdown of the total annual pay for the top executives at SAREPTA THERAPEUTICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. SAREPTA THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. SAREPTA THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Sandesh Mahatme
Executive Vice President, Chief Financial Officer and Chief Business Officer
Total Cash $312,835 Equity $3,011,773 Other $39,413 Total Compensation $3,364,021
David Tyronne Howton Jr.
Executive Vice President, General Counsel and Corporate Secretary
Total Cash $692,320 Equity $4,853,478 Other $157,280 Total Compensation $5,703,078
Gilmore O'Neill M.B., M.M.Sc.
Executive Vice President, Chief Scientific Officer
Total Cash $876,441 Equity $2,898,108 Other $15,500 Total Compensation $3,790,049
William Ciambrone
Executive Vice President, Technical Operations
Total Cash $665,438 Equity $0 Other $14,500 Total Compensation $679,938
Ian M. Estepan
Executive Vice President, Chief Financial Officer
Total Cash $651,371 Equity $4,493,565 Other $32,744 Total Compensation $5,177,680
Louise Rodino-Klapac Ph.D.
Executive Vice President, Chief Scientific Officer
Total Cash $725,522 Equity $6,530,455 Other $13,532 Total Compensation $7,269,509
Douglas S. Ingram
President and Chief Executive Officer
Total Cash $1,274,725 Equity $0 Other $17,222 Total Compensation $1,291,947
Joseph Bratica
Vice President, Corporate Controller
Total Cash $426,868 Equity $473,373 Other $11,645 Total Compensation $911,886
For its 2020 fiscal year, SAREPTA THERAPEUTICS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Douglas S. Ingram CEO Pay $1,291,947 Median Employee Pay $275,247 CEO Pay Ratio 5:1
For its 2019 fiscal year, SAREPTA THERAPEUTICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Claude Nicaise, M.D. Total Cash $561,331
Hans Wigzell, M.D., Ph.D. Total Cash $562,165
M. Kathleen Behrens, Ph.D. Total Cash $606,355
Mary Ann Gray, Ph.D. Total Cash $556,716
Michael W. Bonney Total Cash $547,457
Richard J. Barry Total Cash $574,365

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.